Free Trial
NASDAQ:BIIB

Biogen (BIIB) Stock Price, News & Analysis

$218.73
+0.92 (+0.42%)
(As of 05/28/2024 ET)
Today's Range
$215.17
$218.92
50-Day Range
$190.52
$235.32
52-Week Range
$189.44
$319.76
Volume
633,169 shs
Average Volume
1.17 million shs
Market Capitalization
$31.85 billion
P/E Ratio
27.31
Dividend Yield
N/A
Price Target
$288.46

Biogen MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.65 Rating Score
Upside/​Downside
31.9% Upside
$288.46 Price Target
Short Interest
Healthy
2.41% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.65
Upright™ Environmental Score
News Sentiment
0.60mentions of Biogen in the last 14 days
Based on 39 Articles This Week
Insider Trading
Selling Shares
$19,817 Sold Last Quarter
Proj. Earnings Growth
12.32%
From $15.59 to $17.51 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.84 out of 5 stars

Medical Sector

32nd out of 931 stocks

Biological Products, Except Diagnostic Industry

3rd out of 154 stocks

BIIB stock logo

About Biogen Stock (NASDAQ:BIIB)

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

BIIB Stock Price History

BIIB Stock News Headlines

The Biggest Biotechnology Company in Europe
The Biggest Publicly Traded Biotech Company
Biogen (NASDAQ:BIIB) Earns "Buy" Rating from HC Wainwright
Deep Dive Into Biogen Stock: Analyst Perspectives (17 Ratings)
See More Headlines
Receive BIIB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biogen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/24/2024
Today
5/28/2024
Next Earnings (Estimated)
7/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:BIIB
CUSIP
09062X10
Employees
7,570
Year Founded
1978

Price Target and Rating

Average Stock Price Target
$288.46
High Stock Price Target
$373.00
Low Stock Price Target
$200.00
Potential Upside/Downside
+32.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.65
Research Coverage
26 Analysts

Profitability

Net Income
$1.16 billion
Pretax Margin
13.69%

Debt

Sales & Book Value

Annual Sales
$9.66 billion
Cash Flow
$18.42 per share
Book Value
$102.14 per share

Miscellaneous

Free Float
145,364,000
Market Cap
$31.70 billion
Optionable
Optionable
Beta
-0.01

Social Links

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. Christopher A. Viehbacher (Age 63)
    President, CEO & Director
    Comp: $4.07M
  • Mr. Michael R. McDonnell CPA (Age 60)
    Executive VP & CFO
    Comp: $2.21M
  • Ms. Susan H. Alexander Esq.Ms. Susan H. Alexander Esq. (Age 67)
    Executive VP & Chief Legal Officer
    Comp: $1.95M
  • Ms. Robin C. Kramer (Age 58)
    Senior VP & Chief Accounting Officer
  • Mr. Charles E. Triano
    Senior VP & Head of Investor Relations
  • Ms. Natacha Gassenbach
    Chief Communication Officer & Head of Corporate Affairs
  • Mr. Fraser Hall
    President & Head of Intercontinental Region
  • Dr. Wolfram Schmidt
    President & Head of Europe
  • Ms. Kendra Thomas
    Head of Global Workforce Diversity, Equity & Inclusion and People Relations

BIIB Stock Analysis - Frequently Asked Questions

Should I buy or sell Biogen stock right now?

26 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last twelve months. There are currently 9 hold ratings and 17 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BIIB shares.
View BIIB analyst ratings
or view top-rated stocks.

What is Biogen's stock price target for 2024?

26 Wall Street analysts have issued 1-year price targets for Biogen's stock. Their BIIB share price targets range from $200.00 to $373.00. On average, they anticipate the company's stock price to reach $288.46 in the next twelve months. This suggests a possible upside of 31.9% from the stock's current price.
View analysts price targets for BIIB
or view top-rated stocks among Wall Street analysts.

How have BIIB shares performed in 2024?

Biogen's stock was trading at $258.77 at the start of the year. Since then, BIIB shares have decreased by 15.5% and is now trading at $218.73.
View the best growth stocks for 2024 here
.

Are investors shorting Biogen?

Biogen saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 3,480,000 shares, an increase of 10.5% from the April 30th total of 3,150,000 shares. Based on an average daily volume of 1,220,000 shares, the days-to-cover ratio is presently 2.9 days. Approximately 2.4% of the company's stock are short sold.
View Biogen's Short Interest
.

When is Biogen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, July 23rd 2024.
View our BIIB earnings forecast
.

How were Biogen's earnings last quarter?

Biogen Inc. (NASDAQ:BIIB) announced its earnings results on Wednesday, April, 24th. The biotechnology company reported $3.67 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.45 by $0.22. The biotechnology company had revenue of $2.29 billion for the quarter, compared to analyst estimates of $2.31 billion. Biogen had a net margin of 12.07% and a trailing twelve-month return on equity of 14.83%. The firm's revenue for the quarter was down 7.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.40 earnings per share.
Read the conference call transcript
.

What guidance has Biogen issued on next quarter's earnings?

Biogen updated its FY 2024 earnings guidance on Wednesday, April, 24th. The company provided earnings per share (EPS) guidance of 15.000-16.000 for the period, compared to the consensus estimate of 15.460. The company issued revenue guidance of -.

What is Michel Vounatsos' approval rating as Biogen's CEO?

394 employees have rated Biogen Chief Executive Officer Michel Vounatsos on Glassdoor.com. Michel Vounatsos has an approval rating of 86% among the company's employees. 72.0% of employees surveyed would recommend working at Biogen to a friend.

What other stocks do shareholders of Biogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Amgen (AMGN), Walt Disney (DIS), Intel (INTC), Micron Technology (MU) and Boeing (BA).

Who are Biogen's major shareholders?

Biogen's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (11.38%), Van ECK Associates Corp (1.19%), Price T Rowe Associates Inc. MD (1.09%), Clearbridge Investments LLC (1.07%), Bank of New York Mellon Corp (0.95%) and RA Capital Management L.P. (0.51%). Insiders that own company stock include Alfred Sandrock, Brian S Posner, Eric K Rowinsky, Ginger Gregory, Priya Singhal and Susan H Alexander.
View institutional ownership trends
.

How do I buy shares of Biogen?

Shares of BIIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Biogen have any subsidiaries?
The following companies are subsidiares of Biogen: BIIB Colombia S.A.S., Biogen (Argentina) SRL, Biogen (Bermuda) Technologies Ltd., Biogen (Czech Republic) s.r.o., Biogen (Denmark) A/S, Biogen (RTP) Realty LLC, Biogen Australia PTY Ltd, Biogen Austria GmbH, Biogen B.V., Biogen Belgium N.V./S.A., Biogen Biotechnology (Shanghai) Co. Ltd, Biogen Brasil Produtos Farmaceuticos LTDA, Biogen Canada Inc., Biogen Chesapeake LLC, Biogen Chile Spa, Biogen Digital Health Inc., Biogen Estonia OU, Biogen Finland OY, Biogen Foundation Inc., Biogen France S.A.S., Biogen GmbH, Biogen Holding I LLC, Biogen Holding II LLC, Biogen Hong Kong Limited, Biogen Hungary KFT, Biogen Idec (Ireland) Ltd., Biogen Idec Biotech India Pvt. Ltd., Biogen Idec Limited, Biogen Idec Research Ltd., Biogen Idec Uruguay SA, Biogen International GmbH, Biogen International Holding Limited, Biogen International Neuroscience GmbH, Biogen Italia S.R.L., Biogen Japan Ltd., Biogen Korea LLC, Biogen Latvia SIA, Biogen Lithuania UAB, Biogen Luxembourg Holding S.a.r.l., Biogen MA Inc., Biogen Management Services GmbH, Biogen Manufacturing Holding LLC, Biogen Mexico S. DE R.L. DE C.V., Biogen NZ Biopharma Ltd., Biogen Netherlands B.V., Biogen New Ventures Inc., Biogen Norway AS, Biogen Pharma d.o.o., Biogen Pharma farmacevtska in biotehnoloska druzba d.o.o., Biogen Poland Sp. z.o.o., Biogen Portugal Sociedade Farmaceutica Unipessoal Lda., Biogen Realty Corporation, Biogen Realty Limited Partnership, Biogen SRO Inc., Biogen Slovakia s.r.o., Biogen Spain S.L., Biogen Sweden AB, Biogen Swiss Investments GmbH, Biogen Swiss Manufacturing GmbH, Biogen Switzerland AG, Biogen Switzerland Holdings GmbH, Biogen Taiwan Limited, Biogen Therapeutics Inc., Biogen Turkey Ilac Ticaret Limited Sirketi, Biogen U.S. Corporation, Biogen U.S. Limited Partnership, Biogen U.S. Pacific LLC, Biogen U.S. West Corporation, Conforma Therapeutics, Conforma Therapeutics Corporation, Convergence Pharmaceuticals, Convergence Pharmaceuticals Holdings Ltd., Convergence Pharmaceuticals Limited, Eidetica Biopharma GmbH, Fumapharm, IDEC Pharmaceuticals Corporation, NightstaRx Limited, Nightstar Europa Limited, Nightstar Inc., Nightstar Therapeutics Limited, Nightstar Therapeutics plc, Old Convergence Pharmaceuticals Limited, Panima Pharmaceuticals AG, Silver Acquisition Co. Ltd., Stromedix Inc., Stromedix Inc., Syntonix Pharmaceuticals Inc., TYSABRI, and Tungsten Bidco Limited.
Read More
This page (NASDAQ:BIIB) was last updated on 5/28/2024 by MarketBeat.com Staff

From Our Partners